Cipla targets South African asthma market with breath activated inhaler

By Gareth Macdonald

- Last updated on GMT


Related tags Asthma

Cipla has launched a breath activated inhaler in South Africa.

The product – known as Synchrobreathe – delivery a dose when the user inhalers, which will help sufferers of obstructive airway diseases – asthma and COPD, for example – manage their diseases more effectively according to Cipla Medpro CEO, Paul Miller.

Incorrect use of inhalers and non-adherence to treatment are major contributors to the poor levels of asthma control we experience in South Africa​” Miller said.

South Africa has one of the highest asthma death rates in the world. According to a 2014 study by the Global Asthma Network​ around 15,000 people die from the disease each year.

Related topics Drug Delivery Delivery technologies

Related news

Related suppliers

Follow us


View more